<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Miglustat: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Miglustat: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Miglustat: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10244" href="/d/html/10244.html" rel="external">see "Miglustat: Drug information"</a> and <a class="drug drug_patient" data-topicid="11198" href="/d/html/11198.html" rel="external">see "Miglustat: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F196682"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Opfolda;</li>
<li>Yargesa;</li>
<li>Zavesca</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867565"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>SANDOZ Miglustat;</li>
<li>Zavesca</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1025378"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F12958851"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2461cfdc-7445-49dc-9024-38bdd8caea03">Niemann-Pick Type C disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Niemann-Pick Type C disease:</b> Limited data available (Heron 2012; Patterson 2012): <b>Note:</b> Therapy is recommended for patients with neurological, cognitive, or psychiatric disease manifestations (Patterson 2012). Infant data is very limited; reported infant neurological effects (aside from seizures) have included hypotonia, dysphagia, feeding difficulties (onset: 5 to 12 months of age); earliest reported miglustat therapy is 7 months of age (DiRoccoa 2012; Heron 2012). Doses may be initiated slowly and adjusted for tolerability, particularly GI effects (diarrhea which may require dietary and pharmacologic management (Heron 2012; Patterson 2012). Several months of therapy may be necessary to see clinical benefit (eg, 6 to 12 months) (Patterson 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">BSA ≤0.47 m<sup>2</sup>: 100 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &gt;0.47 to 0.73 m<sup>2</sup>: 100 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &gt;0.73 to 0.88 m<sup>2</sup>: 100 mg 3 times daily</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &gt;0.88 to 1.25 m<sup>2</sup>: 200 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &gt;1.25 m<sup>2</sup>: 200 mg 3 times daily</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 200 mg 3 times daily (Zavesca prescribing information [Canada 2012]; Zavesca prescribing information [European Medicines Agency 2012])</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130113"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">
<b>Niemann-Pick Type C disease</b> (Zavesca prescribing [Canada] information 2012):</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 50 to 70 mL/minute/1.73 m<sup>2</sup>: Administer two-thirds of regular BSA adjusted dose in 2 equal doses</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer one-third of regular BSA adjusted dose in 2 equal doses</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Not recommended</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 50 to 70 mL/minute/1.73 m<sup>2</sup>: 200 mg twice daily</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 100 mg twice daily</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Not recommended</p></div>
<div class="block dohp drugH1Div" id="F51130114"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, dosage adjustment unlikely because miglustat is not metabolized by the liver.</p></div>
<div class="block doa drugH1Div" id="F196684"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10244" href="/d/html/10244.html" rel="external">see "Miglustat: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5dd18fb-2647-40dc-8d16-1017f75a35e4">Gaucher disease, type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gaucher disease, type 1:</b>
<i>Zavesca (and generics): </i>
<b>Oral:</b> 100 mg 3 times daily; dose may be reduced to 100 mg 1 to 2 times daily in patients with adverse effects (eg, tremor, diarrhea).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff4b5dba-d6c8-48e1-b75e-957ffe742d16">Niemann-Pick type C disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Niemann-Pick type C disease (off-label use):</b>
<b>Oral:</b> 200 mg 3 times daily (Patterson 2007; Santos-Lozano 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b6faffa-e30a-4747-8142-d4b2d8a0cc67">Pompe disease, late-onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pompe disease (lysosomal acid alpha-glucosidase deficiency), late-onset:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in combination with cipaglucosidase alfa; initiate 2 weeks after last enzyme replacement therapy dose. Dose is based on actual body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Opfolda:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight ≥40 to &lt;50 kg:</i>
<b>Oral: </b>195 mg every other week, 1 hour before cipaglucosidase alfa dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight ≥50 kg: </i>
<b>Oral: </b>260 mg every other week, 1 hour before cipaglucosidase alfa dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Missed doses:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If miglustat dose is missed:</i> Do not administer cipaglucosidase alfa; reschedule next miglustat dose at least 24 hours after last miglustat dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If both miglustat and cipaglucosidase alfa doses are missed:</i> Restart treatment as soon as possible.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991468"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gaucher disease, type 1:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Zavesca (and generics):</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;70 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 70 mL/minute/1.73 m<sup>2</sup>: 100 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 100 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Niemann-Pick type C disease (off-label use) (Zavesca Canadian product monograph):</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;70 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 50 to 70 mL/minute/1.73 m<sup>2</sup>: 200 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 100 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pompe disease (lysosomal acid alpha-glucosidase deficiency), late-onset:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Opfolda:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to 59 mL/minute:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight ≥40 to &lt;50 kg</i>: 130 mg every other week.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight ≥50 kg</i>: 195 mg every other week.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Use is not recommended (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988795"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, dosage adjustment unlikely because miglustat is not metabolized by the liver.</p></div>
<div class="block adr drugH1Div" id="F196654"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Zavesca administered for type 1 Gaucher disease:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Weight loss</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain, diarrhea, flatulence, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia, dizziness, headache, tremor</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Lower limb cramp, muscle cramps</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Menstrual disease</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distention, anorexia, bloating, constipation, dyspepsia, epigastric pain, xerostomia</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Feeling of heaviness (limbs), memory impairment, migraine, paresthesia, peripheral neuropathy, unsteady gait</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Back pain</p>
<p style="text-indent:-2em;margin-left:2em;">Opfolda administered in combination with Pombiliti for late-onset Pompe disease:</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Flushing (2%), increased blood pressure (≤2%), tachycardia (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pruritus (2%), skin rash (4%), urticaria (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distention (4%), abdominal pain (2%), constipation (≤2%), diarrhea (6%), dysgeusia (2%), dyspepsia (≤2%), nausea (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Decreased platelet count (≤2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (≤2%), chills (2%), dizziness (5%), headache (8%), malaise (≤2%), pain (≤2%), paresthesia (≤2%), tremor (≤2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (≤2%), muscle spasm (2%), myalgia (≤2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Flank pain (≤2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Dyspnea (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing (any indication): Nervous system: Psychosis</p></div>
<div class="block coi drugH1Div" id="F196667"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Pregnancy (Opfolda only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to miglustat or any component of the formulation; females who are or may become pregnant.</p></div>
<div class="block war drugH1Div" id="F196652"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea: Observed in the majority of patients, many also reported weight loss (within first 12 months of treatment). Diarrhea decreased over time with continued treatment, and may respond to diet modification (eg, reduction of sucrose, lactose and other carbohydrate intake), taking miglustat between meals, and/or to anti-diarrheal medications. If diarrhea occurs during treatment, instruct patients to avoid foods with high carbohydrate content. If symptoms persist, evaluate patients for underlying GI disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral neuropathy: Peripheral neuropathy has been reported; neurologic monitoring is required. Weigh risk versus benefit of therapy if patient develops symptoms (eg, numbness and tingling); treatment discontinuation may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Platelet counts decreased: Mild decrease in platelet counts (without bleeding) has been observed in patients with type 1 Gaucher disease switched from enzyme replacement therapy; monitor platelet counts during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tremor: New-onset or exacerbations of existing tremor may occur. Tremor typically begins within the first month of treatment and may resolve over time (1 to 3 months) or respond to dosage reduction. Treatment discontinuation may be necessary if tremor does not respond within days of dose reduction.</p>
<p style="text-indent:0em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: Should be administered under the supervision of a physician experienced in treatment of Gaucher disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Registry: A registry has been established and all patients with Gaucher disease, and physicians who treat Gaucher disease are encouraged to participate. Information on the International Collaborative Gaucher Group (ICGG) Gaucher Registry may be obtained at https://www.registrynxt.com or by calling 1-888-404-4413.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878551"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Growth reductions, both weight and height, has been reported in pediatric patients with Neimann-Pick type C disease on miglustat therapy; initially with therapy, a weight loss was observed that may be accompanied with or followed by a decrease in height velocity. Monitor height and weight with therapy, assess risk/benefit periodically of miglustat therapy (Zavesca prescribing information [European Medicines Agency 2012]).</p></div>
<div class="block foc drugH1Div" id="F196662"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Opfolda: 65 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yargesa: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zavesca: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block geq drugH1Div" id="F196649"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323414"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (migLUstat Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $321.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Opfolda Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">65 mg (per each): $39.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Yargesa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $321.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zavesca Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $225.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867566"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zavesca: 100 mg [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block admp drugH1Div" id="F52613338"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">May be administered with or without food; administration between meals may decrease the incidence of diarrhea. Doses should be taken at the same time each day at regular intervals If patient is unable to tolerate or swallow capsule whole and powder is administered, mix powder into a liquid immediately prior to use (do not store); sweetening agents are not expected to interact (data on file [Actelion pharmaceuticals]).</p></div>
<div class="block adm drugH1Div" id="F196664"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Opfolda: Swallow capsules whole only with unsweetened beverages; do not consume other beverages or food for at least 2 hours before and at least 2 hours after administration. Administer 1 hour before IV cipaglucosidase alfa.</p>
<p style="text-indent:-2em;margin-left:4em;">Zavesca (and generics): May be administered with or without food; administration between meals may decrease the incidence of diarrhea. Capsules should be taken at the same time each day at regular intervals. If patient is unable to tolerate or swallow capsule whole and powder is administered, mix powder into a liquid immediately prior to use (do not store); sweetening agents are not expected to interact (data on file [Actelion Pharmaceuticals Ltd 2011])</p></div>
<div class="block sts drugH1Div" id="F196677"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Opfolda: Store in original container at 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) permitted. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Zavesca (and generics): Store at 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) permitted. <b>Note:</b> Extended storage information may be available; contact product manufacturer to obtain current recommendations.</p></div>
<div class="block usep drugH1Div" id="F53567866"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not a therapeutic option (eg, due to allergy, hypersensitivity, or poor venous access) (FDA approved in adults); has also been used to treat Neimann-Pick Type C Disease</p></div>
<div class="block mst drugH1Div" id="F10193844"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MigLUstat may be confused with migALAstat, miglitol.</p>
<p style="text-indent:-2em;margin-left:4em;">Opfolda may be confused with Opdivo.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zavesca: Brand name for miglustat [US, Canada, and multiple international markets], but also brand name for escitalopram [in multiple international markets; ISMP April 21, 2010]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299712"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221699"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block dic drugH1Div" id="F196669"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Patients with diarrhea should avoid foods with high carbohydrate content.</p></div>
<div class="block rep_considerations drugH1Div" id="F55195496"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">When miglustat is used in combination with cipaglucosidase alfa for Pompe disease (lysosomal acid alpha-glucosidase deficiency), evaluate pregnancy status prior to use; verify the patient is not pregnant prior to treatment initiation. Patients who may become pregnant should use effective contraception during therapy with cipaglucosidase alfa and for at least 60 days after the last dose.</p>
<p style="text-indent:0em;margin-top:2em;">Based on a 6-week study of 7 healthy patients, miglustat is not expected to decrease male fertility.</p></div>
<div class="block pri drugH1Div" id="F196668"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to miglustat may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled type 1 Gaucher disease is associated an increased risk of spontaneous abortion; maternal hepatosplenomegaly and thrombocytopenia may also occur and lead to adverse pregnancy outcomes.</p>
<p style="text-indent:0em;margin-top:2em;">When used in combination with cipaglucosidase alfa for Pompe disease (lysosomal acid alpha-glucosidase deficiency), miglustat is contraindicated during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53567867"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Neurologic evaluations baseline and repeated every 6 months; platelet count; renal function; growth parameters in pediatric patients (height, weight, head circumference) (Patterson 2012)</p></div>
<div class="block pha drugH1Div" id="F196651"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Miglustat competitively and reversibly inhibits the enzyme needed to produce glycosphingolipids and decreases the rate of glycosphingolipid glucosylceramide formation. Glucosylceramide accumulates in type 1 Gaucher disease, causing complications specific to this disease. In patients receiving cipaglucosidase alfa, miglustat reduces endogenous inactivation of cipaglucosidase alfa-atga in the blood.</p></div>
<div class="block phk drugH1Div" id="F196666"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Opfolda: ~94 L; Zavesca: 83 to 105 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: No binding to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: No evidence of metabolism in humans.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Opfolda: ~6 hours; Zavesca: 6 to 7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Opfolda: 2 to 3 hours; Zavesca: 2 to 2.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Opfolda: 10 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51159565"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Limited data suggests that the clearance of miglustat decreases 40% and 60% with mild and moderate renal impairment, respectively. A decreased clearance of 70% has been suggested in patients with severe renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F196670"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Glitir | Zavesca</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Miglustat g.l. | Miglustat Gen.Orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Miglustat Gen.Orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Miglustat g.l. | Miglustat Gen.Orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Miglustat dipharma | Zavesca</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Miglustat accord | Miglustat axunio | Miglustat bluefish | Miglustat dipharma | Miglustat Gen.Orph | Yargesa | Zavesca</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Miglustat Gen.Orph</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Miglustat accord | Miglustat dipharma | Zavesca</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Miglustat accord | Miglustat Gen.Orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Miglustat accord | Miglustat bluefish | Miglustat dipharma | Miglustat Gen.Orph | Yargesa | Zavesca</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Yargesa | Zavesca</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Miglustat Gen.Orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Miglustat accord | Miglustat dipharma | Yargesa | Zavesca</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Brazaves</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Miglustat Gen.Orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Miglustat bluefish | Miglustat genorph | Zavesca</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Miglustat accord | Zavesca</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Yargesa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Miglustato Accord | Miglustato gen orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Miglustat bluefish | Miglustat Gen.Orph | Zavesca</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Miglustat g.l.pharma | Zavesca</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zavesca</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Miglustat gl pharma</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22704015">
<a name="22704015"></a>Di Rocco M, Dardis A, Madeo A, Barone R, Fiumara A. Early miglustat therapy in infantile Niemann-Pick disease type C. <i>Pediatr Neurol</i>. 2012;47(1):40-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/22704015/pubmed" id="22704015" target="_blank">22704015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25888393">
<a name="25888393"></a>Fecarotta S, Romano A, Della Casa R, et al. Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. <i>Orphanet J Rare Dis</i>. 2015;10:22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/25888393/pubmed" id="25888393" target="_blank">25888393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29625568">
<a name="29625568"></a>Geberhiwot T, Moro A, Dardis A, et al; International Niemann-Pick Disease Registry (INPDR). Consensus clinical management guidelines for Niemann-Pick disease type C. <i>Orphanet J Rare Dis</i>. 2018;13(1):50. doi:10.1186/s13023-018-0785-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/29625568/pubmed" id="29625568" target="_blank">29625568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22676771">
<a name="22676771"></a>Héron B, Valayannopoulos V, Baruteau J, et al. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. <i>Orphanet J Rare Dis</i>. 2012;7:36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/22676771/pubmed" id="22676771" target="_blank">22676771</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Opfolda (miglustat) [prescribing information]. Philadelphia, PA: Amicus Therapeutics US LLC; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32324281">
<a name="32324281"></a>Patterson MC, Garver WS, Giugliani R, et al. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: a large retrospective observational study. <i>J Inherit Metab Dis</i>. 2020;43(5):1060-1069. doi:10.1002/jimd.12245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/32324281/pubmed" id="32324281" target="_blank">32324281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22572546">
<a name="22572546"></a>Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. <i>Mol Genet Metab</i>. 2012;106(3):330-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/22572546/pubmed" id="22572546" target="_blank">22572546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17689147">
<a name="17689147"></a>Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomized controlled study. <i>Lancet Neurol</i>. 2007;6(9):765-772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/17689147/pubmed" id="17689147" target="_blank">17689147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30111334">
<a name="30111334"></a>Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann-Pick disease type C patients: a review. <i>Orphanet J Rare Dis</i>. 2018;13(1):140. doi:10.1186/s13023-018-0844-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/30111334/pubmed" id="30111334" target="_blank">30111334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26807415">
<a name="26807415"></a>Santos-Lozano A, Villamandos GD, Sanchis-Gomar F, et al. Niemann-Pick disease treatment: a systematic review of clinical trials. <i>Ann Transl Med</i>. 2015;3(22):360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/26807415/pubmed" id="26807415" target="_blank">26807415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35696615">
<a name="35696615"></a>Koç Yekedüz M, Öncül Ü, Köse E, Eminoğlu FT. Probable miglustat-induced psychosis in a child with Niemann-Pick Type C. <i>Clin Neuropharmacol</i>. 2022;45(4):107-109. doi:10.1097/WNF.0000000000000511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miglustat-pediatric-drug-information/abstract-text/35696615/pubmed" id="35696615" target="_blank">35696615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zavesca.1">
<a name="Zavesca.1"></a>Zavesca (miglustat) [prescribing information]. Titusville, NJ: Actelion Pharmaceuticals US Inc; August 2022.</div>
</li>
<li>
<div class="reference">
                  Zavesca (miglustat) [prescribing information]. Freiburg, Germany: Actelion Pharmaceuticals Deutschland GmbH; February 2012.</div>
</li>
<li>
<div class="reference">
                  Zavesca (miglustat) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; January 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 109479 Version 101.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
